Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.47 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081685 | 1.00 | RIPK1 (0.48) | RIPK1NR1H2NR1H3HTRA1GPR119 | |
| SCHEMBL27752838 | 1.00 | RIPK1 (0.48) | RIPK1NR1H2NR1H3HTRA1GPR119 | |
| SCHEMBL15267083 | 0.90 | RIPK1 (0.50) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL24366348 | 0.90 | RIPK1 (0.50) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL26984212 | 0.89 | RIPK1 (0.49) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL26993797 | 0.89 | RIPK1 (0.49) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL26984184 | 0.87 | NR1H2 (0.47) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL27128033 | 0.87 | NR1H2 (0.47) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL28212559 | 0.86 | RIPK1 (0.49) | RIPK1NR1H2NR1H3GPR119STS | |
| SCHEMBL17782223 | 0.85 | RIPK1 (0.50) | RIPK1NR1H2NR1H3HTRA1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | RIPK1 4522/4885NR1H2 408/4885NR1H3 280/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | RIPK1 4792/4885NR1H2 76/4885NR1H3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.